MedTrace Logo

The Optimal Treatment for Treatment-resistant Schizophrenia

NCT02926976 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2019-03-13

No results posted yet for this study

Summary

The Optimal Treatment for Treatment-resistant Schizophrenia

Conditions

Interventions

DRUG

Risperidone with Clozapine

Risperidone may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia

DRUG

Aripiprazole with Clozapine

Aripiprazole may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia

DRUG

sodium valproate with Clozapine

sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia

DEVICE

modified electroconvulsive therapy(MECT) with Clozapine

modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia

DEVICE

Magnetic seizure therapy(MST) with Clozapine

Magnetic seizure therapy(MST) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia

DEVICE

clozapine

clozapine may be used in the treatment of treatment-resistant schizophrenia

Sponsors & Collaborators

  • Shanghai Mental Health Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2019-09-30
Completion
2019-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02926976 on ClinicalTrials.gov